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ABSTRACT
The first descriptions of haemophilia A were reported in the second century AD, with the first
modern description by John Conrad Otto in 1803. Historically, the natural history of
haemophilia A was associated with very high rates morbidity and mortality, often following
trivial accidents. Although treatment options for haemophilia A have been revolutionised in
recent decades, haemophilia A remains a hereditary disease of concern and factor replacement
products remain the mainstay of treatment.
As such, patients with haemophilia can carry huge burdens, particularly when a complication
such as a FVIII inhibitor is present. A recently approved novel therapeutic, Emicizumab-kxwh,
has offered an unexpected and alternative approach to haemophilia A therapy. This
recombinant, humanized, bi-specific antibody provides patients with effective haemostasis,
empowerment of self-administration, and an overall improved quality of life. For patients with
FVIII inhibitors, Emicizumab-kxwh offers a simple treatment mechanism that can efficiently
overcome deleterious antibodies as the antibody bridges FIX and FX, mimicking the function
of FVIII without sharing structural homology or biochemical properties. Considering this, the
literature and clinical trials available to date have been critically analysed and discussed herein.
This review aims to explore the advantages, disadvantages, and any potential need for caution
with Emicizumab-kxwh.
INTRODUCTION
Haemophilia A is an X-linked coagulation disorder characterised by quantitative or qualitative
defects in coagulation factor VIII (FVIII), also known as the antihaemophilic factor. This
disorder is thought to have been reported as early as the second century AD (Franchini and
Mannucci, 2014). However, modern descriptions were observed in the 1800’s when it was
noted that males from the same family (known as ‘bleeders’) suffered from several bleeding
events with apparent asymptomatic female transmission (Schramm, 2014). The disease was not
well understood at the time, but it was determined that males should not be circumcised if two
brothers of the family had already died from excessive bleeding following the procedure
(Franchini and Mannucci, 2014). The Babylonian Talmud indicates that if a woman has lost
her first two sons after circumcision, she is exempt from the obligation to have the third son
circumcised (Rosendaal, Smit and Briët, 1991). Haemophilia is commonly referred to as the
royal disease, as Queen Victoria was a carrier of Haemophilia B which lead to several royal
family members being affected by the disease (Franchini and Mannucci, 2014). One of the first
clinically accurate descriptions of haemophilia A was reported in 1803 by John Conrad Otto.
His understanding of the disease was “if least scratch is made on the skin of some of them, as
mortal a haemorrhage will eventually ensue.” He also was capable of observing the inheritance
pattern by stating that “it is a surprising circumstance that the males only are subject to this

28

Volume 2 Issue 1

IUJHS

06/2022

strange affection, and that all of them are not liable to it” (Otto, 1803). The first descriptions
of the genetics of haemophilia were published in 1820 by Nasse culminating in Nasse’s law,
which states that haemophilia is transmitted entirely by unaffected females to their sons (Nasse,
1820).
Today, haemophilia A can be classified based on the severity of the FVIII deficiency present.
Patients with mild haemophilia present with 5 - 40% of normal FVIII levels (>0.05-0.4 IU/mL);
moderate haemophilia A with 1-5% of normal FVIII levels (0.01-0.05 UI/mL); and, severe
haemophilia A with <1% of normal FVIII levels present (<0.01 IU/mL) (Bolton-Maggs and
Pasi, 2003). Approximately 50-60% of patients with haemophilia A present with severe
disease.
The qualitative or quantitative defects in coagulation FVIII observed in haemophilia A are
hereditary. Genetic mutations in the FVIII gene, found on the long arm of the X chromosome
at position Xq28, are responsible for this hereditary disease. Although more than 2800 different
mutations of the F8 gene are documented in the Human Gene Mutation Database, the most
common mutation identified in haemophilia A is the intron 22 inversion (Inv22) of the F8 gene,
observed in 45% of severe haemophilia A patients (Bolton-Maggs and Pasi, 2003). Inv22 is a
result of homologous intrachromosomal recombination between the F8A gene in intron 22 and
two additional transcribed copies of the F8A gene telomeric and upstream to the F8 gene
(Lakich et al., 1993; De Brasi and Bowen, 2008). While this is a hereditary disorder, it is
noteworthy that Srivastava et al., (2020), report that approximately 30% of cases of
haemophilia, including instances of haemophilia B, arise as a result of spontaneous genetic
variants.
The clinical significance of Haemophilia A is demonstrated by the spontaneous bleeding
episodes often encountered by these patients. Haemophilia A patients (particularly those with
these severe type), can suffer bleeding into joints (haemarthrosis) and soft tissues, muscle
haematomas, gastrointestinal bleeding, central nervous system bleeding and excessive bleeding
following trauma or surgery (Mansouritorghabeh, 2015; Srivastava et al., 2020) Haemarthrosis
is characteristic of the severe form of haemophilia A and is most seen in the knees, elbows,
ankles and wrists (Mansouritorghabeh, 2015). Both haemarthrosis and muscle haematomas can
lead to restricted movements in the joints and limbs affected (Mansouritorghabeh, 2015).
Historically, these episodes could even be fatal for the patient as there were little or no treatment
options available (Schramm, 2014). In the 1950’s and 1960’s, patients could be treated with
fresh plasma. However, this form of therapy did not offer sufficient FVIII to treat serious
bleeds, and fatalities were common (Franchini and Mannucci, 2014). At the time, this plasma
was not treated with pathogen reduction techniques. Subsequently, many mortalities were seen
because of human immunodeficiency virus (HIV) infection and hepatitis virus infections
(Franchini and Mannucci, 2014).
However, today there are several safe treatment options available for haemophilia A patients.
The most common treatments utilised are recombinant FVIII concentrates that have been
available since the 1990s (Casademunt et al., 2012). These FVIII concentrates act as a
replacement for the deficient or defective physiological FVIII. These have been successful in
reducing the rate of bleeding in haemophilia A patients by 90% (Morfini and Marchesini,
2020). Despite their success, these FVIII concentrates have still been associated with
breakthrough bleeding when used as a prophylaxis. The annual bleeding rate (ABR) for patients
using FVIII concentrates as a prophylaxis varies from 0-11.8 events per annum (Sun et al.,,
2021). A study conducted by Musso et al., 2008, observed that 65.7% of patients (mainly with
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severe haemophilia A) using FVIII concentrates as prophylaxis experienced some form of
spontaneous bleeding. However, this study also reports that 85.4% of bleeding events can be
successfully treated with one or two infusions of FVIII concentrates. The most notable issue
associated with these FVIII concentrates is the development of antibodies/inhibitors against
them. Twenty percent of haemophilia A patients will develop an inhibitor against FVIII
concentrate treatments, mainly in patients with severe haemophilia A (Walsh et al. , 2015;
Paisley and Wight, 2003). These inhibitors can render treatment 2-3 times more expensive by
comparison to those who do not develop an inhibitor (Guh et al., 2012). More clinically
significant, the presence of inhibitors means that bleeding episodes are more difficult to prevent
and treat using FVIII concentrates.
With the above taken into consideration, FVIII concentrates have provided a considerable
treatment option for haemophilia A patients. However, their drawbacks revealed a space on the
market for a more efficient drug with a potentially easier administration. The relatively new
bispecific antibody emicizumab-kxwh (HEMLIBRA, Genentech, Inc.) meets these
requirements.

PHARMACODYNAMICS OF EMICIZUMAB-KXWH
The function of active FVIII (FVIIIa) in vivo is to act as a non-enzymatic cofactor for FIXa for
the activation of FX in the presence of phospholipids and calcium ions (Mazurkiewicz-Pisarek
et al., 2016). This is part of the intrinsic coagulation pathway that leads to further activation of
prothrombin to thrombin and subsequently allow for clot formation when fibrinogen converts
to fibrin. Therefore, in haemophilia A, this mechanism is decreased or lost.
Emicizumab-kxwh (sold under the brand name HEMLIBRA) developed by Genentech, Inc. is
a bispecific antibody that binds to both FIXa and FX, allowing it to mimic the function of FVIII
to maintain haemostasis (Kitazawa et al., 2017). The function of the antibody is based on the
mechanism by which FVIIIa interacts with both FIXa and FX, as shown Figure 1 (Kitazawa et
al., 2017). Despite mimicking the function of FVIII, emicizumab-kxwh does not display
structural homology with physiological FVIII or FVIII concentrates. This property allows it to
evade the immunogenicity of inhibitors against FVIII that may be present in haemophilia A
patients (Le Quellec and Negrier, 2018). FVIII and emicizumab-kxwh also have different
biochemical properties (Müller et al., 2019). Emicizumab-kxwh binds specifically to the EGF1
domain of FIXa and the EGF2 domain of FX, despite this domain being present in other vitamin
K dependent factors (European Medicines Agency, 2018).
The route of administration for emicizumab-kxwh is subcutaneous (Yoneyama et al., 2018)
which is advantageous over intravenous administration (as seen with FVIII concentrates) as it
allows for self-administration (Le Quellec and Negrier, 2018). There are a variety of dosing
regimens available (1.5 mg/kg, 3 mg/kg or 6 mg/kg) which means emicizumab-kxwh can be
administered weekly, fortnightly or monthly (Blair, 2019). This is highly convenient rather than
administering intravenous FVIII concentrates two to three times per week, depending on the
dosing regimen of FVIII required (Srivastava et al., 2020). However, this strict regimen is
necessary for FVIII concentrates due to their short half-life (Parisi and Kumar, 2021). In
contrast, emicizumab-kxwh has a half-life of approximately 30 days and a high bioavailability
following subcutaneous administration (Yoneyama et al., 2018).
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(a)

(b)

(c)

Figure 1: (a) Schematic representation of the mechanism of action of emicizumab-kxwh in the
physiological coagulation cascade. (b) Mechanism of action of physiological FVIII in vivo.
(c) Mechanism of action of emicizumab-kxwh. Adapted from BioRender.com
(https://biorender.com/).
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EFFICACY OF EMICIZUMAB-KXWH
Several studies have been conducted on the efficacy and safety of Emicizumab-kxwh in patients
see table 1. HAVEN 1 successfully demonstrates that emicizumab-kxwh is capable of
significantly reducing the ABR in comparison to haemophilia A patients receiving no
prophylaxis. The ABR for treated bleeds was 2.9 in those receiving 1.5 mg/kg per week
whereas the ABR for those receiving no prophylaxis was 23.3, an increase of 87% (Oldenburg
et al., 2017). However, most haemophilia A patients will receive some form of treatment so
those receiving no prophylaxis do not fairly represent the ‘normal’ population. It was
interestingly noted that participants in this trial who had previously been treated with episodic
bypassing agents had an ABR of 37.7 (21.6 of which were treated bleeds). This then decreased
to an ABR of 4.1 (1.7 of which were treated) when using emicizumab-kxwh. These ABR values
were obtained in the first 24 weeks of the trial, and significant changes were seen in the long
term. After one year of using emicizumab-kxwh, the ABR for participants was 0.6, 0 of which
were treated bleeds (Oldenburg et al., 2017). This indicates that emicizumab-kxwh may be a
more effective prophylaxis in the longer term.
HAVEN 2 reported similar findings regarding the efficacy of emicizumab-kxwh in paediatric
patients with inhibitors. However, this study investigated different dosing regimens of the drug
and found that 3 mg/kg per 2 weeks appeared to be the most efficient. Participants receiving 3
mg/kg per 2 weeks had an ABR of 1.5 (0.2 of which were treated). Those receiving 6 mg/kg
per 4 weeks had an ABR of 3.8 (2.2 of which were treated) and those receiving 1.5 mg/kg per
week had an ABR of 3.2 (0.3 of which were treated) (Young et al., 2019). However, caution
should be taken when interpreting these ABRs as the higher ABR reported in the group of
participants receiving 6 mg/kg per 4 weeks was primarily associated with two participants: one
had several joint bleeds, and the other participant developed anti-drug antibodies (ADA).
Interestingly, these ADAs had neutralising potential and there was very little emicizumabkxwh
detectable in this participants bloodstream (Young et al., 2019). In total, four participants
developed ADAs as part of HAVEN 2. Two of these participants had ADAs without
neutralising potential, which did not have any effect on the efficacy of the drug. However, the
other two participants developed ADAs with neutralising potential. One of these participants
had to drop out of the study with many bleeding events reported (as mentioned above).
However, the other participant had decreased (but still detectable) levels of plasma
emicizumab-kxwh. This participant had a ‘normal’ APTT and reported no bleeding events
throughout the study, despite the presence of ADAs with neutralising potential. Follow up after
the study showed that this participant had become ADA-negative and normal plasma
emicizumab-kxwh levels were reported (Young et al., 2019). To date, no clear predisposing
factors for the development of ADAs in these participants has been identified.
Unlike HAVEN 1 and HAVEN 2, HAVEN 3 studied the efficacy of emicizumab-kxwh in
participants without inhibitors. All participants of this study had previously received
prophylactic or episodic FVIII concentrates (Mahlangu et al., 2018). This study showed similar
findings to HAVEN 1 as 56% and 60% of participants receiving 1.5 mg/kg per week and 3
mg/kg per 2 weeks, respectively, had no treated bleeding events whereas all participants (n=18)
receiving no prophylaxis reported treated bleeds in the first 24 weeks of the study. HAVEN 1
showed that there was an 87% increase in treated bleeds when receiving no prophylaxis
compared to when receiving emicizumab-kxwh in the first 24 weeks of the study. This study is
a useful comparison of emicizumab-kxwh and FVIII concentrates efficacy as it includes
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intraindividual analysis. Mahlangu et al., (2018), report that the ABR decreased by 68% when
a participant moved from FVIII prophylaxis to emicizumab-kxwh prophylaxis.
HAVEN 4 was a smaller study that focused on the 6 mg/kg per 4 weeks dosing regimen in
mainly adult participants. This study reported that the ABR for participants after 24 weeks of
emicizumab-kxwh was 4.5 (2.4 of which needed to be treated) (Pipe et al., 2019). Interestingly,
this study also states that 100% of the participants prefer emicizumab-kxwh over their previous
treatment of intravenous FVIII (Pipe et al., 2019).
While other studies were and continue to be carried out, the results obtained in HAVEN 1,
HAVEN 2, HAVEN 3 and HAVEN 4 were vital in the approval of this drug for routine
prophylactic use, as they were the largest clinical trial programmes for haemophilia A to date
(Young et al., 2019). Additional studies include HAVEN 5, HOHOEMI (Shima et al., 2019)
and STASEY. Results observed in the HOHOEMI study correlate with other paediatric studies
such as HAVEN 2 and confirm the safety of emicizumab-kxwh for routine use. The HOHOEMI
study also revealed that participants could participate in physical activity with moderate or high
risk while maintain a low ABR (Shima et al., 2019). Historically, high risk physical activity
was a risk for haemophilia A patients and activities such as swimming, walking, rowing,
sailing, and table tennis were encouraged (Srivastava et al., 2020).
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Table 1: Summary of Emicizumab-kxwh clinical trials
Name
study

of Participants
enrolled

Emicizumabkxwh Number of Current
dose investigated participants status

References

HAVEN 1

Adults
and 1.5 mg/kg per
adolescents
week
with inhibitors

109

Completed (Oldenburg
et al., 2017)

HAVEN 2

Children with
inhibitors

88

Completed (Young
et
al., 2019)

HAVEN 3

Adults
and 1.5 mg/kg per
week
adolescents
3 mg/kg per 2
without
weeks
inhibitors

152

Active, not (Mahlangu
recruiting et al., 2018)

HAVEN 4

Adults
and 6 mg/kg per 4
adolescents
weeks
with
or
without
inhibitors

41

Active, not (Pipe et al.,
recruiting 2019)

HAVEN 5

Adults
and 1.5 mg/kg per
week
adolescents
with
or 6 mg/kg per 4
weeks
without
inhibitors

70

Active, not No
results
recruiting available

13

Completed (Shima
et
al., 2019)

193

Completed (HoffmannLa
Roch
e,
2021a)

HOHOEMI Children
without
inhibitors
STASEY
(Safety
study)

1.5 mg/kg per
week
3 mg/kg per 2
weeks
6 mg/kg per 4
weeks

3 mg/kg per 2
weeks
6 mg/kg per 4
weeks

Adults
and 1.5 mg/kg per
adolescents
week
with inhibitors

CURRENT GUIDELINES FOR THE USE OF EMICIZUMAB-KXWH
Emicizumab-kxwh is a relatively new haemophilia A therapy and has only been approved for
routine use in recent years. Emicizumab-kxwh is Food and Drug Administration (FDA)
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approved for routine prophylaxis in adult and paediatric patients with congenital haemophilia
A and with inhibitors since November 2017, and without inhibitors since October 2018 (U.S.
Food & Drug Administration, 2018). In Europe, the drug is approved for use by the European
Medicines Agency (EMA) in haemophilia A patients with inhibitors since February 2018 and
for patients with severe haemophilia A without inhibitors since January 2019 (Krumb et al.,
2021).
With three dosing regimens of emicizumab-kxwh available, there are variations seen between
countries on the guidelines employed. The World Haemophilia Federation recommend that
emicizumab-kxwh should be used for haemophilia A patients with an inhibitor and can be used
for patients without an inhibitor (Srivastava et al., 2020). Most countries recommend a loading
dose of 3 mg/kg per week for four weeks, followed by a maintenance dosing regimen
(Hoffmann-La Roche, 2021; European Medicines Agency, 2018). The maintenance dose is
often based on physician and patient / caregiver preference in terms of adherence to the regimen
(Holstein et al., 2020). However, some countries have individual dosing recommendations for
certain patient cohorts. For example, in Canada, all three dosing regimens (1.5 mg/kg per week,
3 mg/kg per 2 weeks and 6 mg/kg per month), are available. However, the 6 mg/kg per 4 weeks
regimen is not recommended for paediatric patients or patients weighing <40 kg (HoffmannLa
Roche, 2021). In contrast, the FDA recommend the standard loading dose followed by 1.5
mg/kg per week in the USA (U.S. Food & Drug Administration, 2017). In Ireland, the Health
Products Regulatory Authority has authorised the use of 150 mg/ml and 30 mg/ml solutions
that can be used to administer dosing regimens of 1.5 mg/kg per week, 3 mg/kg per two weeks
or 6 mg/kg per four weeks (Irish Haemophilia Society, 2021).

LABORATORY TESTING FOR PATIENTS ON EMICIZUMAB-KXWH
FDA and EMA approval of emicizumab-kxwh will inevitably lead to an increase in patients
using the drug in the future. This novel drug will likely inflict challenges in clinical laboratories
associated with the monitoring of these patients (Srivastava et al., 2020). Tests that have been
shown to be affected by this drug include the activated partial thromboplastin time (APTT), the
Bethesda clotting-based assay, APTT-based factor assays and activated protein C resistance
assays. As expected, prothrombin time (PT) assays, thrombin time (TT) and chromogenic
factor assays using bovine coagulation factor reagents remain unchanged in haemophilia A
patients prescribed emicizumab-kxwh (Mahlangu et al., 2018).
The APTT is a two-stage assay that can be used as a screening test for haemophilia A and other
coagulation disorders, as well as an assay to monitor drugs such as unfractionated heparin
(Lippi and Favaloro, 2019). It is a simple and cost-efficient assay that has easily lent itself to
automation (Ignjatovic, 2013). The principle of the assay involves detection of a fibrin clot
once the coagulation cascade of patient plasma has been activated by a FXII activator and
calcium chloride. The results are reported in seconds, which is the time to clot formation
(Ignjatovic, 2013). This should be carefully interpreted in patients with a haematocrit >55%,
which is common in paediatric patients, as these patients have a decreased plasma volume, and
the APTT may be increased consequently (Srivastava et al., 2020). In this situation, the bloodto-anticoagulant ratio may need to be altered for accurate results.
Since haemophilia A affects FVIII, haemophilia A patients generally have a prolonged APTT
(Srivastava et al., 2020). In theory, emicizumab-kxwh should affect the results of any assay
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that measures FIX or FX. Patients using emicizumab-kxwh have been reported to have a
shortened APTT, some even within the ‘normal’ range (Bowyer, Kitchen and Maclean, 2020).
This shortened APTT can be seen for as long as 6 months post emicizumab-kxwh treatment
due to the long half-life of the antibody (Uchida et al., 2016). Haemophilia A patients using
FVIII concentrates also experience a shortened APTT result. However, the shortening affect
caused by emicizumab-kxwh is more pronounced and can be evident with subtherapeutic levels
of emicizumab-kxwh because emicizumab-kxwh does not require activation for function as
FVIII concentrates do (Shimonishi et al., 2020; Srivastava et al., 2020).
Despite the widespread use of the APTT assay in laboratories, shortcomings are seen in terms
of standardisation. Unlike the prothrombin time assay, the APTT is reported in seconds,
regardless of what reagents are used. This can lead to varying results between laboratories and
subsequently, results can be difficult to interpret (Ignjatovic, 2013). An example of this was
seen when the APTT of several patients using emicizumab-kxwh was analysed using different
reagents namely Actin, Actin FS, Actin FSL, Pathromtin SL, Synthasil, Synthafax, APTT SP,
STA- PTTA, Cephascreen, CK Prest, Triniclot APTT S, Triniclot ATT HS and Triniclot APTT
Auto. The APTT results obtained varied, with only eight out of thirteen reagents displaying a
constant ‘normal’ APTT (Bowyer, Kitchen and Maclean, 2020). For this reason, the variability
in reagents used in the APTT assay should be considered.
The Bethesda clotting-based assay is a useful method to identify the presence of FVIII
inhibitors in haemophilia A patients. However, as this is a clotting-based assay, the results are
affected by emicizumab-kxwh. Therefore, the World Federation of Haemophilia recommend
that inhibitor levels in emicizumab-kxwh patients should be identified and monitored via a
chromogenic Bethesda assay using bovine reagents (Srivastava et al., 2020). Bovine reagents
are necessary to prevent cross reactivity with emicizumab-kxwh. Bethesda assays involving
human proteins should be restricted to patients not prescribed this drug (Lippi and Favaloro,
2019). Furthermore, FVIII plasma levels are important for haemophilia A patients and may
need to be regularly monitored. When a patient is taking a drug such as emicizumab-kxwh, an
APTT-based factor assay cannot be used for plasma FVIII levels and a chromogenic assay is
necessary (Krumb et al., 2021).
There are suggestions that there is little need to monitor patients using emicizumab-kxwh by
laboratory testing. However, there are concerns that there are risks of procoagulant activity in
patients using this drug, who have a breakthrough bleed and are then prescribed other
procoagulants, such as activated prothrombin complex concentrate (aPCC) (Hartmann et al.,
2018). In the HAVEN 1 trial, two patients experienced thrombotic microangiopathy (TMA)
when treated with >100 U/kg of aPCC daily for more than one day after experiencing a
breakthrough bleed while using emicizumab-kxwh (Oldenburg et al., 2017). This is because
aPCC increases the availability of FIX and FX, resulting in increased thrombin generation and
exaggerated procoagulant activity (Hartmann et al., 2018). These findings suggest that there
should potentially be a standardised monitoring system in place for patients using emicizumabkxwh in the event of a breakthrough bleed.
The traditional APTT is not recommended for monitoring of Haemophilia A patients prescribed
Emicizumab-kxwh because the drug does not provide a true reflection of the coagulation
cascade in vivo, as emicizumab-kxwh does not require activation by other coagulation factors
(Adamkewicz et al., 2020). Most clinical trials involving emicizumabkxwh employed an
ELISA assay to monitor plasma Emicizumab-kxwh levels (Adamkewicz et al., 2020).
However, this is a complex assay that would not be suitable for routine clinical laboratory use
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(Kitazawa et al., 2017). With the clear demand for a reliable clinical assay for the measurement
of emicizumab-kxwh activity, a modified APTT-based FVIII one step assay (OSA) has been
developed (Calhoon et al., 2018, as cited by Müller et al., 2019). This assay has been calibrated
against emicizumab-kxwh and has a higher patient dilution than the traditional APTT-based
FVIII assay (allowing a larger range of emicizumab-kxwh monitoring). Other than this
modification, the assay follows the same principle as the traditional APTT-based FVIII assay
and has been in use commercially in Austria, Germany, and Switzerland. The World
Haemophilia Federation recommend the use of this assay for the monitoring of emicizumabkxwh in patients when necessary (Srivastava et al., 2020). Adamkewicz et al., 2020, found that
this OSA displayed similar emicizumab-kxwh plasma levels when compared to the
complicated and non-commercial ELISA assay employed in the HAVEN clinical trials.
The above demonstrates that there is a possible mechanism of routinely measuring
emicizumab-kxwh activity and patient FVIII plasma levels. However, obstacles may remain
for the analysis of other coagulation factors measured by the APTT assay (FIX, FXII and
FXIII).

BENEFITS OF EMICIZUMAB-KXWH FOR HAEMOPHILIA A PATIENTS
Clinical trials to date illustrate the value of emicizumab-kxwh for haemophilia A patients. This
drug has revolutionised treatment, despite experts expecting gene therapy to be the next step
for haemophilia A (Morfini and Marchesini, 2020). While FVIII concentrates still offer a
substantial prophylactic option, emicizumab-kxwh has demonstrated itself as far superior with
many advantages, primarily the decreased ABR associated with it.
While analysis of the ABR is vital for understanding the efficacy of emicizumab-kxwh, the
quality of life for the patient is also an important factor to consider. The HAVEN 1 study
conducted by Oldenburg et al., 2017, used numerical values to assess the quality of life as
reported by the participants in the trial, with the lower scores indicating a better quality of life.
Those receiving 1.5 mg/kg of emicizumab-kxwh per week had a score of 30.19, while those
receiving no treatment had a score of 57.14 (). Scores were calculated based on answers given
by patients in a questionnaire given to haemophilia A patients prescribed emicizumab-kxwh.
Self-administration of emicizumab-kxwh is hugely advantageous for haemophilia A patients as
it avoids intravenous administration by a healthcare professional two to three times per week
(Pipe et al., 2019; Srivastava et al., 2020) allowing haemophilia A patients to become
competent in their own care. Should it be possible, 84% of all patients admit that they are
willing to self-administer their medication leading to increased patient independence,
satisfaction, and increased knowledge about their drugs (Vanwesemael et al., 2018). There are
several skills required by patients for self-administration of emicizumab-kxwh such as bleed
recognition, record keeping of their regimen and self-infusion skills (Srivastava et al., 2020).
Self-administration of emicizumab-kxwh also eliminates the need for central venous access
devices (CVADs) in paediatric patients which can often become infected, and venous access
in adults which can sometimes be difficult (Srivastava et al., 2020). For paediatric patients and
patients who require care assistants, self-administration may not be possible. A study conducted
by Hoffmann-La Roche, (2021) showed that 100% of care givers preferred emicizumab-kxwh
administration over other haemophilia A prophylactic treatments as it allowed a lower
treatment frequency and had less of an impact on daily activities.
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The main benefit of emicizumab-kxwh can be observed by the report from HAVEN 3 that
demonstrates that the ABR decreased by 68% when a haemophilia A patient moved from FVIII
concentrates prophylaxis to emicizumab-kxwh prophylaxis (Mahlangu et al., 2018). Even
though emicizumab-kxwh is not readily available worldwide, it is thought to be a cost-effective
treatment as it decreases hospital visits, morbidity, and mortality for the patients (Srivastava et
al., 2020). The decreased ABR in conjunction with self-administration and less hospitalisations
and deaths provides clear evidence for patients to move to emicizumab-kxwh therapy when
possible. Although thus far, congenital haemophilia A has been the focus of studies,
Emicizumab-kxwh has also been reported to be an effective agent to treat acquired haemophilia
A (Knoebl et al., 2021).

DISADVANTAGES OF EMICIZUMAB-KXWH
While emicizumab-kxwh offers several advantages as a haemophilia A prophylaxis over other
therapies, there are also some concerns associated with the drug that should not be overlooked.
Young et al., (2019), reported that nasopharyngitis and site injection reactions were observed
in 37.5% and 30.7%, respectively, of paediatric participants in the HAVEN 2 study. However,
these were all considered non-serious events and did not require treatment. Other adverse
events that have been noted less commonly in patients using emicizumab-kxwh are headaches,
arthralgia, upper respiratory tract infections and pain in extremities (Pipe et al., 2019).
One of the more serious complications that have been observed in patients using
emicizumabkxwh is thrombotic microangiopathy (TMA). This complication has been observed
in two patients using 1.5 mg/kg per week emicizumab-kxwh who experienced a breakthrough
bleed and were treated with aPCC (Oldenburg et al., 2017). Therefore, it is recommended that
patients who experience breakthrough bleeding are treated with episodic recombinant FVII
(rFVII) or other bypassing agents. However, should aPCC be the only bypassing agent
available, the lowest dose expected to achieve haemostasis should be administered (Young et
al., 2019).
A dilemma currently faced by many clinicians prescribing patients with emicizumab-kxwh is
the efficacy of the drug over time and the development of ADAs with neutralising potential.
ADAs have been reported in clinical trials, with two participant showing neutralising potential
causing emicizumab-kxwh to have a loss of efficacy (Young et al., 2019). This may be a cause
for concern as more patients begin to use the drug and long-term data is unavailable.
Additionally, should patients develop ADAs after using emicizumab-kxwh for some time, a
change of therapy may be required. As 20% of patients develop inhibitors to FVIII concentrates
(Walsh et al., 2015) and there are concerns that older / adult patients using FVIII concentrates
for the first time may have a large immune response to the drug there are suggestions that age
should be aforethought when considering a switch of therapies at a later age (Krishna and
Nadler, 2016). Perhaps this could be overcome by administering low doses of FVIII
concentrates infrequently in conjunction with emicizumab-kxwh.
While emicizumab-kxwh offers many advantages to haemophilia A patients, it is not available
in many parts of the world and several countries still rely on fresh frozen plasma (FFP).
Developed countries have moved away from the use of FFP due to the risks associated with
bacterial and viral pathogens being present (Srivastava et al., 2020). Therefore, treatment
options for patients often rely on the cost and availability of therapies.
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CONCLUSIONS
Despite the prospect that gene therapy could have revolutionised haemophilia A therapy,
unexpectedly emicizumab-kxwh, a bi-specific antibody, has done just that. This therapy offers
a convenient and highly effective alternative to FVIII concentrates that have been the standard
approach to therapy for several years. Furthermore, emicizumab-kxwh may be the only
effective therapy available for bleeding control for some haemophilia A patients with high titres
of FVIII inhibitors. However, this is not to suggest that gene therapy will not offer a permanent
treatment option in the future.
Suggestions have been made that emicizumab-kxwh should be administered as it demonstrates
superiority to FVIII concentrates and offers several advantages to haemophilia A patients (Le
Quellec and Negrier, 2018; Oldenburg et al., 2017). It is now the recommended treatment by
the World Haemophilia Federation for patients who possess a FVIII inhibitor and are at risk of
haemorrhage (Srivastava et al., 2020). However, as there is an increase in the administration of
this drug, there may need to be a standardised approach to laboratory testing considered.
The future regarding therapies for haemophilia A is optimistic since the approval of
emicizumab-kxwh for routine use. Current and future trials include the investigation of
emicizumab-kxwh during minor surgical procedures and the investigation of the efficacy of
emicizumab-kxwh in moderate and severe haemophilia A patients playing sports. This may
provide evidence that haemophilia A patients, even those with the severe form, could be
empowered to live a relatively normal life without too much concern for bleeding events.
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